Biological aspects and candidate biomarkers for psychotic bipolar disorder: A systematic review

Psychiatry and Clinical Neurosciences

Volumn 70, Issue 6, 2016, Pages 227-244

  Buoli, Massimiliano ^a,b   Caldiroli, Alice ^a   Cumerlato Melter, Claudia ^a   Serati, Marta ^a   de Nijs, Jessica ^b   Altamura, A Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

biomarkers; bipolar disorder; psychoneurobiology; psychopathology; psychotic symptoms

Indexed keywords

BIOLOGICAL MARKER; FUNGUS ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; KYNURENIC ACID; MUSCARINIC RECEPTOR; PRASTERONE SULFATE; PROGESTERONE; TUMOR NECROSIS FACTOR; VON WILLEBRAND FACTOR;

5HTTLPR GENE; ANDROGEN BLOOD LEVEL; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; BRAIN METABOLISM; BRAIN SIZE; BRAIN VENTRICLE; CEREBROSPINAL FLUID LEVEL; CHROMOSOME 13Q; CHROMOSOME 16P; COGNITIVE DEFECT; COMT GENE; DAOA GENE; EVENT RELATED POTENTIAL; EXECUTIVE FUNCTION; FLUENCY DISORDER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; HIPPOCAMPUS; HUMAN; MEMORY DISORDER; NRG1 GENE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROGESTERONE BLOOD LEVEL; PSYCHOTIC BIPOLAR DISORDER; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; VERBAL MEMORY; WORKING MEMORY;

BIOMARKERS; BIPOLAR DISORDER; HUMANS;

EID: 85011341300     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12386     Document Type: Review

References (145)

1. Frey BN, Andreazza AC, Houenou J et al. Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust. N. Z. J. Psychiatry 2013; 47: 321–332.
2. Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: Focus on BDNF, inflammatory markers, and endothelial function. Curr. Psychiatry Rep. 2013; 15: 425.
3. Dickerson F, Stallings C, Origoni A et al. A combined marker of inflammation in individuals with mania. PLoS ONE 2013; 8: e73520.
4. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B represents a new biomarker for mood disorders. Curr. Drug Targets 2013; 14: 1237–1248.
5. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC. Psychotic depression and mortality. Am. J. Psychiatry 2003; 160: 574–576.
6. Zenisek R, Thaler N, Ringdahl E et al. C-29 * Intellectual ability and functional outcome in bipolar disorder and schizophrenia. Arch. Clin. Neuropsychol. 2014; 29: 582–583.
7. Kessing LV. Subtypes of depressive episodes according to ICD-10: Prediction of risk of relapse and suicide. Psychopathology 2003; 36: 285–291.
8. Buoli M, Caldiroli A, Altamura AC. Psychotic versus non-psychotic major depressive disorder: A comparative naturalistic study. Asian J. Psychiatr. 2013; 6: 333–337.
9. Altamura AC, Buoli M, Caldiroli A et al. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: A naturalistic study. J. Affect. Disord. 2015; 182: 70–75.
10. Lin A, Reniers RL, Wood SJ. Clinical staging in severe mental disorder: Evidence from neurocognition and neuroimaging. Br. J. Psychiatry 2013; 54 (Suppl.): s11–s17.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. American Psychiatric Press, Washington, DC, 2000.
12. Kim YK, Myint AM, Lee BH et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 1129–1134.
13. Ganguli R, Yang Z, Shurin G et al. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness. Psychiatry Res. 1994; 51: 1–10.
14. Naudin J, Capo C, Giusano B, Mège JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr. Res. 1997; 26: 227–233.
15. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr. Res. 1999; 37: 97–106.
16. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res. 2000; 44: 165–175.
17. Liu H, Kang Y, Liang J et al. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia. Psychiatry Res. 2012; 198: 329–331.
18. Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia. Psychiatry Clin. Neurosci. 2014; 68: 21–36.
19. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Behav. Rev. 2011; 35: 804–817.
20. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: Focus on acutely ill patients. J. Affect. Disord. 2006; 90: 263–267.
21. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007; 104: 91–95.
22. Ortiz-Domínguez A, Hernández ME, Berlanga C et al. Immune variations in bipolar disorder: Phasic differences. Bipolar Disord. 2007; 9: 596–602.
23. Hope S, Ueland T, Steen NE et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr. Res. 2013; 145: 36–42.
24. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010; 15: 384–392.
25. Suvisaari J, Loo BM, Saarni SE et al. Inflammation in psychotic disorders: A population-based study. Psychiatry Res. 2011; 189: 305–311.
26. Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J. Affect. Disord. 2015; 182: 106–114.
27. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J. Affect. Disord. 2012; 139: 230–239.
28. Demir S, Atli A, Bulut M et al. Neutrophil-lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy. Neuropsychiatr. Dis. Treat. 2015; 11: 2253–2258.
29. Olsson SK, Sellgren C, Engberg G, Landén M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012; 14: 719–726.
30. Severance EG, Dupont D, Dickerson FB et al. Immune activation by casein dietary antigens in bipolar disorder. Bipolar Disord. 2010; 12: 834–842.
31. Severance EG, Gressitt KL, Yang S et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disord. 2014; 16: 230–240.
32. Johansson AG, Nikamo P, Schalling M, Landén M. Polymorphisms in AKR1C4 and HSD3B2 and differences in serum DHEAS and progesterone are associated with paranoid ideation during mania or hypomania in bipolar disorder. Eur. Neuropsychopharmacol. 2012; 22: 632–640.
33. Narayanan B, O'Neil K, Berwise C et al. Resting state electroencephalogram oscillatory abnormalities in schizophrenia and psychotic bipolar patients and their relatives from the bipolar and schizophrenia network on intermediate phenotypes study. Biol. Psychiatry 2014; 76: 456–465.
34. Reite M, Teale P, Rojas DC, Arciniegas D, Sheeder J. Bipolar disorder: Anomalous brain asymmetry associated with psychosis. Am. J. Psychiatry 1999; 156: 1159–1163.
35. Olincy A, Martin L. Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. Am. J. Psychiatry 2005; 162: 43–49.
36. Schulze KK, Hall MH, McDonald C et al. P50 auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. Biol. Psychiatry 2007; 62: 121–128.
37. Sánchez-Morla EM, García-Jiménez MA, Barabash A et al. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. Acta Psychiatr. Scand. 2008; 117: 313–318.
38. Cabranes JA, Ancín I, Santos JL et al. P50 sensory gating is a trait marker of the bipolar spectrum. Eur. Neuropsychopharmacol. 2013; 23: 721–727.
39. Patterson JV, Sandman CA, Ring A, Jin Y, Bunney WE, Jr. An initial report of a new biological marker for bipolar disorder: P85 evoked brain potential. Bipolar Disord. 2009; 11: 596–609.
40. Carroll CA, Kieffaber PD, Vohs JL, O'Donnell BF, Shekhar A, Hetrick WP. Contributions of spectral frequency analyses to the study of P50 ERP amplitude and suppression in bipolar disorder with or without a history of psychosis. Bipolar Disord. 2008; 10: 776–787.
41. Hall MH, Schulze K, Sham P et al. Further evidence for shared genetic effects between psychotic bipolar disorder and P50 suppression: A combined twin and family study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008; 147B: 619–627.
42. Patterson JV, Sandman CA, Jin Y, Kemp AS, Potkin SG, Bunney WE, Jr. Gating of a novel brain potential is associated with perceptual anomalies in bipolar disorder. Bipolar Disord. 2013; 15: 314–325.
43. Hamm JP, Ethridge LE, Shapiro JR et al. Spatiotemporal and frequency domain analysis of auditory paired stimuli processing in schizophrenia and bipolar disorder with psychosis. Psychophysiology 2012; 49: 522–530.
44. Nenadic I, Maitra R, Langbein K et al. Brain structure in schizophrenia vs. psychotic bipolar I disorder: A VBM study. Schizophr. Res. 2015; 165: 212–219.
45. Ratnanather JT, Poynton CB, Pisano DV et al. Morphometry of superior temporal gyrus and planum temporale in schizophrenia and psychotic bipolar disorder. Schizophr. Res. 2013; 150: 476–483.
46. Mahon PB, Lee DS, Trinh H et al. Morphometry of the amygdala in schizophrenia and psychotic bipolar disorder. Schizophr. Res. 2015; 164: 199–202.
47. Laidi C, d'Albis MA, Wessa M et al. Cerebellar volume in schizophrenia and bipolar I disorder with and without psychotic features. Acta Psychiatr. Scand. 2015; 131: 223–233.
48. Lu LH, Zhou XJ, Keedy SK, Reilly JL, Sweeney JA. White matter microstructure in untreated first episode bipolar disorder with psychosis: Comparison with schizophrenia. Bipolar Disord. 2011; 13: 604–613.
49. McDonald C, Bullmore E, Sham P et al. Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder: Computational morphometry study. Br. J. Psychiatry 2005; 186: 369–377.
50. Tighe SK, Reading SA, Rivkin P et al. Total white matter hyperintensity volume in bipolar disorder patients and their healthy relatives. Bipolar Disord. 2012; 14: 888–893.
51. Ivleva EI, Bidesi AS, Keshavan MS et al. Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am. J. Psychiatry 2013; 170: 1285–1296.
52. Yüksel C, McCarthy J, Shinn A et al. Gray matter volume in schizophrenia and bipolar disorder with psychotic features. Schizophr. Res. 2012; 138: 177–182.
53. Tost H, Ruf M, Schmäl C et al. Prefrontal-temporal gray matter deficits in bipolar disorder patients with persecutory delusions. J. Affect. Disord. 2010; 120: 54–61.
54. Radaelli D, Poletti S, Gorni I et al. Neural correlates of delusion in bipolar depression. Psychiatry Res. 2014; 221: 1–5.
55. Rosa PG, Schaufelberger MS, Uchida RR et al. Lateral ventricle differences between first-episode schizophrenia and first-episode psychotic bipolar disorder: A population-based morphometric MRI study. World J. Biol. Psychiatry 2010; 11: 873–887.
56. Fornito A, Yücel M, Wood SJ et al. Anterior cingulate cortex abnormalities associated with a first psychotic episode in bipolar disorder. Br. J. Psychiatry 2009; 194: 426–433.
57. Foland-Ross LC, Thompson PM, Sugar CA et al. Investigation of cortical thickness abnormalities in lithium-free adults with bipolar I disorder using cortical pattern matching. Am. J. Psychiatry 2011; 168: 530–539.
58. Womer FY, Wang L, Alpert KI et al. Basal ganglia and thalamic morphology in schizophrenia and bipolar disorder. Psychiatry Res. 2014; 223: 75–83.
59. Mathew I, Gardin TM, Tandon N et al. Medial temporal lobe structures and hippocampal subfields in psychotic disorders: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. JAMA Psychiatry 2014; 71: 769–777.
60. Arnold SJ, Ivleva EI, Gopal TA et al. Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). Schizophr. Bull. 2015; 41: 233–249.
61. Skudlarski P, Schretlen DJ, Thaker GK et al. Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am. J. Psychiatry 2013; 170: 886–898.
62. Kumar J, Iwabuchi S, Oowise S, Balain V, Palaniyappan L, Liddle PF. Shared white-matter dysconnectivity in schizophrenia and bipolar disorder with psychosis. Psychol. Med. 2015; 45: 759–770.
63. Sarrazin S, Poupon C, Linke J et al. A multicenter tractography study of deep white matter tracts in bipolar I disorder: Psychotic features and interhemispheric disconnectivity. JAMA Psychiatry 2014; 71: 388–396.
64. Strasser HC, Lilyestrom J, Ashby ER et al. Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: A pilot study. Biol. Psychiatry 2005; 57: 633–639.
65. Edmiston EE, Wang F, Kalmar JH et al. Lateral ventricle volume and psychotic features in adolescents and adults with bipolar disorder. Psychiatry Res. 2011; 194: 400–402.
66. Anticevic A, Savic A, Repovs G et al. Ventral anterior cingulate connectivity distinguished nonpsychotic bipolar illness from psychotic bipolar disorder and schizophrenia. Schizophr. Bull. 2015; 41: 133–143.
67. Baker JT, Holmes AJ, Masters GA et al. Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder. JAMA Psychiatry 2014; 71: 109–118.
68. Khadka S, Meda SA, Stevens MC et al. Is aberrant functional connectivity a psychosis endophenotype? A resting state functional magnetic resonance imaging study. Biol. Psychiatry 2013; 74: 458–466.
69. Anticevic A, Brumbaugh MS, Winkler AM et al. Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol. Psychiatry 2013; 73: 565–573.
70. Brandt CL, Eichele T, Melle I et al. Working memory networks and activation patterns in schizophrenia and bipolar disorder: Comparison with healthy controls. Br. J. Psychiatry 2014; 204: 290–298.
71. Avery SN, Williams LE, Woolard AA, Heckers S. Relational memory and hippocampal function in psychotic bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2014; 264: 199–211.
72. Altamura AC, Bertoldo A, Marotta G et al. White matter metabolism differentiates schizophrenia and bipolar disorder: A preliminary PET study. Psychiatry Res. 2013; 214: 410–414.
73. Pearlson GD, Wong DF, Tune LE et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch. Gen. Psychiatry 1995; 52: 471–477.
74. Zubieta JK, Huguelet P, Ohl LE et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: Sex differences and cognitive correlates. Am. J. Psychiatry 2000; 157: 1619–1628.
75. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol. Psychiatry 2001; 49: 110–116.
76. Selva G, Salazar J, Balanzá-Martínez V et al. Bipolar I patients with and without a history of psychotic symptoms: Do they differ in their cognitive functioning? J. Psychiatr. Res. 2007; 41: 265–272.
77. Hill SK, Reilly JL, Harris MS et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr. Res. 2009; 113: 167–175.
78. Simonsen C, Sundet K, Vaskinn A et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr. Bull. 2011; 37: 73–83.
79. Zanelli J, Reichenberg A, Morgan K et al. Specific and generalized neuropsychological deficits: A comparison of patients with various first-episode psychosis presentations. Am. J. Psychiatry 2010; 167: 78–85.
80. Hill SK, Reilly JL, Keefe RS et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am. J. Psychiatry 2013; 170: 1275–1284.
81. Caletti E, Paoli RA, Fiorentini A et al. Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: Preliminary data. Front. Hum. Neurosci. 2013; 7: 661.
82. Kim D, Kim JW, Koo TH, Yun HR, Won SH. Shared and distinct neurocognitive endophenotypes of schizophrenia and psychotic bipolar disorder. Clin. Psychopharmacol. Neurosci. 2015; 13: 94–102.
83. Reichenberg A, Harvey PD, Bowie CR et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 2009; 35: 1022–1029.
84. Ancín I, Cabranes JA, Santos JL, Sánchez-Morla E, Barabash A. Executive deficits: A continuum schizophrenia-bipolar disorder or specific to schizophrenia? J. Psychiatr. Res. 2013; 47: 1564–1571.
85. Mojtabai R, Bromet EJ, Harvey PD, Carlson GA, Craig TJ, Fennig S. Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders. Am. J. Psychiatry 2000; 157: 1453–1460.
86. Liu SK, Chiu CH, Chang CJ, Hwang TJ, Hwu HG, Chen WJ. Deficits in sustained attention in schizophrenia and affective disorders: Stable versus state-dependent markers. Am. J. Psychiatry 2002; 159: 975–982.
87. Jabben N, Arts B, Krabbendam L, van Os J. Investigating the association between neurocognition and psychosis in bipolar disorder: Further evidence for the overlap with schizophrenia. Bipolar Disord. 2009; 11: 166–177.
88. Ivleva EI, Morris DW, Osuji J et al. Cognitive endophenotypes of psychosis within dimension and diagnosis. Psychiatry Res. 2012; 196: 38–44.
89. Frydecka D, Eissa AM, Hewedi DH et al. Impairments of working memory in schizophrenia and bipolar disorder: The effect of history of psychotic symptoms and different aspects of cognitive task demands. Front. Behav. Neurosci. 2014; 8: 416.
90. Strauss GP, Thaler NS, Matveeva TM et al. Predicting psychosis across diagnostic boundaries: Behavioral and computational modeling evidence for impaired reinforcement learning in schizophrenia and bipolar disorder with a history of psychosis. J. Abnorm. Psychol. 2015; 124: 697–708.
91. Allen DN, Randall C, Bello D et al. Are working memory deficits in bipolar disorder markers for psychosis? Neuropsychology 2010; 24: 244–254.
92. Martinez-Aran A, Torrent C, Tabares-Seisdedos R et al. Neurocognitive impairment in bipolar patients with and without history of psychosis. J. Clin. Psychiatry 2008; 69: 233–239.
93. Savitz J, van der Merwe L, Stein DJ, Solms M, Ramesar R. Neuropsychological status of bipolar I disorder: Impact of psychosis. Br. J. Psychiatry 2009; 194: 243–251.
94. Levy B, Weiss RD. Neurocognitive impairment and psychosis in bipolar I disorder during early remission from an acute episode of mood disturbance. J. Clin. Psychiatry 2010; 71: 201–206.
95. Delgado VB, Chaves ML. Mood congruence phenomenon in acutely symptomatic mania bipolar I disorder patients with and without psychotic symptoms. Cogn. Neuropsychiatry 2013; 18: 477–490.
96. Levy B, Medina AM, Weiss RD. Cognitive and psychosocial functioning in bipolar disorder with and without psychosis during early remission from an acute mood episode: A comparative longitudinal study. Compr. Psychiatry 2013; 54: 618–626.
97. Glahn DC, Bearden CE, Cakir S et al. Differential working memory impairment in bipolar disorder and schizophrenia: Effects of lifetime history of psychosis. Bipolar Disord. 2006; 8: 117–123.
98. Glahn DC, Bearden CE, Barguil M et al. The neurocognitive signature of psychotic bipolar disorder. Biol. Psychiatry 2007; 62: 910–916.
99. Aminoff SR, Hellvin T, Lagerberg TV, Berg AO, Andreassen OA, Melle I. Neurocognitive features in subgroups of bipolar disorder. Bipolar Disord. 2013; 15: 272–283.
100. Bora E, Vahip S, Akdeniz F et al. The effect of previous psychotic mood episodes on cognitive impairment in euthymic bipolar patients. Bipolar Disord. 2007; 9: 468–477.
101. Daros AR, Ruocco AC, Reilly JL, Harris MS, Sweeney JA. Facial emotion recognition in first-episode schizophrenia and bipolar disorder with psychosis. Schizophr. Res. 2014; 153: 32–37.
102. Ruocco AC, Reilly JL, Rubin LH et al. Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Schizophr. Res. 2014; 158: 105–112.
103. Thaler NS, Allen DN, Sutton GP, Vertinski M, Ringdahl EN. Differential impairment of social cognition factors in bipolar disorder with and without psychotic features and schizophrenia. J. Psychiatr. Res. 2013; 47: 2004–2010.
104. Cheng R, Juo SH, Loth JE et al. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol. Psychiatry 2006; 11: 252–260.
105. Kremeyer B, García J, Müller H et al. Genome-wide linkage scan of bipolar disorder in a Colombian population isolate replicates loci on chromosomes 7p21-22, 1p31, 16p12 and 21q21-22 and identifies a novel locus on chromosome 12q. Hum. Hered. 2010; 70: 255–268.
106. Park N, Juo SH, Cheng R et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol. Psychiatry 2004; 9: 1091–1099.
107. Maziade M, Roy MA, Chagnon YC et al. Shared and specific susceptibility loci for schizophrenia and bipolar disorder: A dense genome scan in Eastern Quebec families. Mol. Psychiatry 2005; 10: 486–499.
108. Maziade M, Chagnon YC, Roy MA, Bureau A, Fournier A, Merette C. Chromosome 13q13-q14 locus overlaps mood and psychotic disorders: The relevance for redefining phenotype. Eur. J. Hum. Genet. 2009; 17: 1034–1042.
109. Bureau A, Chagnon YC, Croteau J et al. Follow-up of a major psychosis linkage site in 13q13-q14 reveals significant association in both case–control and family samples. Biol. Psychiatry 2013; 74: 444–450.
110. Belmonte Mahon P, Pirooznia M, Goes FS et al. Genome-wide association analysis of age at onset and psychotic symptoms in bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011; 156B: 370–378.
111. Psychosis Endophenotypes International Consortium; Wellcome Trust Case-Control Consortium, Bramon E, Pirinen M, Strange A et al. A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol. Psychiatry 2014; 75: 386–397.
112. Hall MH, Chen CY, Cohen BM et al. Genomewide association analyses of electrophysiological endophenotypes for schizophrenia and psychotic bipolar disorders: A preliminary report. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2015; 168B: 151–161.
113. Goes FS, Zandi PP, Miao K et al. Mood-incongruent psychotic features in bipolar disorder: Familial aggregation and suggestive linkage to 2p11-q14 and 13q21-33. Am. J. Psychiatry 2007; 164: 236–247.
114. Goes FS, Hamshere ML, Seifuddin F et al. Genome-wide association of mood-incongruent psychotic bipolar disorder. Transl. Psychiatry 2012; 2: e180.
115. Hamshere ML, Schulze TG, Schumacher J et al. Mood-incongruent psychosis in bipolar disorder: Conditional linkage analysis shows genome-wide suggestive linkage at 1q32.3, 7p13 and 20q13.31. Bipolar Disord. 2009; 11: 610–620.
116. Meier S, Mattheisen M, Vassos E et al. Genome-wide significant association between a 'negative mood delusions' dimension in bipolar disorder and genetic variation on chromosome 3q26.1. Transl. Psychiatry 2012; 2: e165.
117. Martucci L, Wong AH, De Luca V et al. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr. Res. 2006; 84: 214–221.
118. Kerner B, Jasinska AJ, DeYoung J, Almonte M, Choi OW, Freimer NB. Polymorphisms in the GRIA1 gene region in psychotic bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009; 150B: 24–32.
119. Roche S, Cassidy F, Zhao C et al. Candidate gene analysis of 21q22: Support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007; 144: 1094–1096.
120. Grover D, Verma R, Goes FS et al. Family-based association of YWHAH in psychotic bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009; 150B: 977–983.
121. Goes FS, Willour VL, Zandi PP et al. Family-based association study of neuregulin 1 with psychotic bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009; 150B: 693–702.
122. Müller DJ, Zai CC, Shinkai T, Strauss J, Kennedy JL. Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. Bipolar Disord. 2011; 13: 198–207.
123. Ho LW, Furlong RA, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC. Genetic associations with clinical characteristics in bipolar affective disorder and recurrent unipolar depressive disorder. Am. J. Med. Genet. 2000; 96: 36–42.
124. De Pradier M, Gorwood P, Beaufils B, Adès J, Dubertret C. Influence of the serotonin transporter gene polymorphism, cannabis and childhood sexual abuse on phenotype of bipolar disorder: A preliminary study. Eur. Psychiatry 2010; 25: 323–327.
125. Ospina-Duque J, Duque C, Carvajal-Carmona L et al. An association study of bipolar mood disorder (type I) with the 5-HTTLPR serotonin transporter polymorphism in a human population isolate from Colombia. Neurosci. Lett. 2000; 292: 199–202.
126. Choi KY, Yoon HK, Kim YK. Association between serotonin-related polymorphisms in 5HT2A, TPH1, TPH2 genes and bipolar disorder in Korean population. Psychiatry Investig. 2010; 7: 60–67.
127. Green EK, Raybould R, Macgregor S et al. Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch. Gen. Psychiatry 2005; 62: 642–648.
128. Prata DP, Breen G, Osborne S, Munro J, St Clair D, Collier DA. An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr. Genet. 2009; 19: 113–116.
129. Schulze TG, Ohlraun S, Czerski PM et al. Genotype–phenotype studies in bipolar disorder showing association between the DAOA/G30 locus and persecutory delusions: A first step toward a molecular genetic classification of psychiatric phenotypes. Am. J. Psychiatry 2005; 162: 2101–2108.
130. Basterreche N, Dávila R, Zumárraga M et al. Biological correlates of the congruence and incongruence of psychotic symptoms in patients with type 1 bipolar disorder. Neuropsychobiology 2008; 58: 111–117.
131. Dalvie S, Horn N, Nossek C, van der Merwe L, Stein DJ, Ramesar R. Psychosis and relapse in bipolar disorder are related to GRM3, DAOA, and GRIN2B genotype. Afr. J. Psychiatry 2010; 13: 297–301.
132. Dávila R, Zumárraga M, Basterreche N, Arrúe A, Zamalloa MI, Anguiano JB. Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder–a preliminary report. J. Affect. Disord. 2006; 92: 277–281.
133. Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, Smeraldi E. Association between catechol-O-methyltransferase Val(108/158)met polymorphism and psychotic features of bipolar disorder. J. Affect. Disord. 2010; 125: 341–344.
134. Leszczyńska-Rodziewicz A, Szczepankiewicz A, Narożna B et al. Possible association between haplotypes of the FKBP5 gene and suicidal bipolar disorder, but not with melancholic depression and psychotic features, in the course of bipolar disorder. Neuropsychiatr. Dis. Treat. 2014; 10: 243–248.
135. Bellivier F, Laplanche JL, Schürhoff F et al. Apolipoprotein E gene polymorphism in early and late onset bipolar patients. Neurosci. Lett. 1997; 233: 45–48.
136. Leszczyńska-Rodziewicz A, Szczepankiewicz A, Dmitrzak-Węglarz M, Skibińska M, Hauser J. Association between functional polymorphism of the AVPR1b gene and polymorphism rs1293651 of the CRHR1 gene and bipolar disorder with psychotic features. J. Affect. Disord. 2012; 138: 490–493.
137. Zhao L, Lin Y, Lao G et al. Association study of dopamine receptor genes polymorphism with cognitive functions in bipolar I disorder patients. J. Affect. Disord. 2015; 170: 85–90.
138. Lee YJ, Kim YK. The impact of glycogen synthase kinase 3β gene on psychotic mania in bipolar disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011; 35: 1303–1308.
139. Hong CJ, Lai IC, Liou LL, Tsai SJ. Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder. Neurosci. Lett. 2004; 355: 69–72.
140. Raybould R, Green EK, MacGregor S et al. Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol. Psychiatry 2005; 57: 696–701.
141. Pae CU, Yoon SJ, Patkar A et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism and mood disorders: A preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 1326–1329.
142. Gaysina D, Cohen-Woods S, Chow PC et al. Association of the dystrobrevin binding protein 1 gene (DTNBP1) in a bipolar case–control study (BACCS). Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009; 150B: 836–844.
143. Tamminga CA, Ivleva EI, Keshavan MS et al. Clinical phenotypes of psychosis in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP). Am. J. Psychiatry 2013; 170: 1263–1274.
144. Altamura AC, Serati M, Albano A, Paoli RA, Glick ID, Dell'Osso B. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur. Arch. Psychiatry Clin. Neurosci. 2011; 261: 489–508.
145. Altamura AC, Buoli M, Serati M. Duration of illness and duration of untreated illness in relation to drug free response in psychiatry disorders. Neuropsychiatry 2011; 1: 81–90.